Breaking News, Collaborations & Alliances

Amorfix Enters AD Assay Pact

Provides access to EP-AD assay technology for Phase I trial

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Amorfix Life Sciences Ltd. has signed an agreement with a major global pharmaceutical company providing access to its EP-AD assay technology for an Alzheimer’s disease diagnostic assay for Phase I studies. Terms of the agreement were not disclosed.   The EP-AD diagnostic assay can identify early-stage AD patients and patients with mild cognitive impairment (MCI) who are at high risk of developing AD. The EP-AD assay measures levels of Abeta aggregates, a biomarker of the disease. The pharm...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters